Medtech 2026: Five Trends Reshaping Global Healthcare Markets

The medical technology industry is being reshaped by broader structural forces that extend far beyond product innovation. From procurement policies in China to the rise of ambulatory care, from disrupted supply chains to the ripple effects of GLP-1 therapies and the growing importance of platform ecosystems, medtech companies are now required to adjust their strategies with a much wider lens. Clarivate's recent analysis, "Medtech Trends to Watch in 2026," highlights five trends that will have lasting implications for companies, investors, and healthcare systems around the world.

1. China's Volume-Based Procurement Is Rewiring Global Pricing Dynamics

Mainland China's national volume-based procurement (VBP) scheme has evolved from a cost-containment measure into a demanding market-structuring instrument. The latest procurement round includes more sophisticated anchor-price logic, deeper price compression, and allocation mechanisms that favor domestic manufacturers. For multinational medtech companies, this no longer only affects their China business; it is setting expectations for price and volume across other global markets. Commoditization in major categories such as stents, orthopedics and consumables is likely to spread as procurement policies become more benchmarked.

Strategically, multinationals must reconsider portfolio designs, decide which product lines to fight for, and increasingly partner with local players to participate in domestic innovation. The days when companies could treat China merely as a scaling market for global products are drawing to a close.

2. Outpatient Settings Become New Commercial Priority

The migration of procedures from hospitals to ambulatory surgery centers (ASCs) and other outpatient settings is a non-cyclical shift that is changing the economics of the industry. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 OPPS/ASC Final Rule expands the Covered Procedure List and further phases out the inpatient-only list. This allows more complex interventions, such as cardiac ablation, to be delivered in lower-cost, community-based settings.

For medtech manufacturers, this transformation requires a rethink of product design, pricing, and the sales model. Devices need to be optimized for usability in outpatient settings, and value propositions may need to be communicated to a wider set of buyers, including healthcare administrators and physician-owners, rather than just hospital procurement. Companies that participate in this ecosystem capture long-term growth in sectors such as orthopedics, general surgery and cardiovascular care.

3. Supply Chain and Trade Pressures Reshape Manufacturing Footprints

Tariff exposure and geopolitical tensions are forcing medtech groups to rethink where and how they manufacture. Fluctuating material prices and supply chain shocks have also shown the fragility of concentrated production bases. Manufacturers today are deliberately diversifying suppliers and creating multi-region footprints that can adapt to changing political and trade conditions.

This is not only an operational matter. It is increasingly a source of competitive differentiation. Larger companies use their scale to invest in flexible manufacturing and digital supply chain technology, putting smaller competitors at a disadvantage. In addition, category portfolio rebalancing and cost structure innovation will be critical. In the long run, the geography of medtech innovation and production is likely to reflect geopolitical dynamics more strongly than before.

4. GLP-1 Therapies Ripple Across Care Pathways and Device Demand

The fast adoption of GLP-1 receptor agonists for obesity and related metabolic diseases is having a systematic effect on procedure volume and device demand. Although bariatric surgery remains the most effective approach for substantial and sustained weight loss, the popularity of GLP-1 medications is moving the center of gravity in weight management. Newer patient pathways are emerging, and they affect device categories from diabetes care to sleep apnea and cardiovascular monitoring. For medical device manufacturers, the speed and direction of those effects will not be uniform. The impact varies by indication, procedure type and time horizon. Companies with exposure to bariatric interventions must monitor patient flow, while adjacent device makers need to assess changing patient pools and potential expansion of monitoring or diagnostic needs.

This trend illustrates how the boundaries between pharmaceutical therapy and medical devices are becoming increasingly fluid. Strategic planning processes need a cross-sector perspective that accounts for total metabolic disease management.

5. Enabling Technologies Prompt a Shift to Platform-Based Competition

Beyond standalone devices, competitive advantage is increasingly derived from integrated systems of robotics, imaging, navigation, and digital workflow technologies. These enable clinical planning, precise execution, and connected post-operative care. The industry is now seeing a shift from single-product value propositions to full platform architectures that anchor entire service lines, deepen customer relationships, and open new data-driven business models.

Not all actors will have the financial or technical strength to build broad proprietary platforms. Newly emerging open-platform systems provide flexibility and could alter the competitive balance. Companies must decide whether they are platform creators, selective subsystem providers, or integrators, and align acquisitions and R&D accordingly. This is likely to accelerate consolidation and change ecosystem positioning over the next decade.

Strategic Considerations for a Transforming Sector

Executives in the medical technology industry need to understand that all of these forces interact. China VBP pressure reinforces global pricing pressure; site-of-care shifts alter device demand and require cost-efficient product design; supply chain complexity increases the price of success; the GLP-1 revolution changes the trajectory of care pathways; and enabling technologies commoditize individual devices while elevating the importance of complete ecosystems. As a result, corporate strategy must span regulatory policy, procurement, manufacturing, commercial model, and technology platform investments. The winners will likely be those who can analyze market-level changes with precision and adapt their portfolios in an environment of uncertainty.

Looking ahead, the next three to ten years will be defined by ongoing diversification of manufacturing and sales footprints; an expansion of value-based care that shifts more risk to providers; the deployment of digital and data-enabled capabilities; and continued breakthroughs in end-to-end patient care. Patient populations in emerging markets, alongside regulatory changes in developed countries, will produce fragmented opportunities. The medtech companies that emerge as global leaders will be those that treat these structural shifts as a benchmark for their own corporate strategy rather than merely a set of temporary headwinds.

---

Source: Clarivate, "5 medtech trends to watch in 2026", April 28, 2026. Available at: https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026